Hetrombopag
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Hengqu |
Other names | Rafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H22N4O5 |
Molar mass | 458.474 g·mol−1 |
3D model (JSmol) | |
| |
|
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia.[1][2][3]
It is a non-peptide small‐molecule thrombopoietin receptor agonist.[4]
In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.[4]
References
[edit]- ^ Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, et al. (January 2022). "Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study". Annals of Translational Medicine. 10 (2): 30. doi:10.21037/atm-21-4361. PMC 8848441. PMID 35282136.
- ^ Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. (February 2021). "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia". Journal of Hematology & Oncology. 14 (1): 37. doi:10.1186/s13045-021-01047-9. PMC 7905908. PMID 33632264.
- ^ Chang H, Pan L, Jia Y, Xiang B, Huang X, Guo Y, et al. (2023). "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood. 142: 5631. doi:10.1182/blood-2023-185469.
- ^ a b Syed YY (September 2021). "Hetrombopag: First Approval". Drugs. 81 (13): 1581–1585. doi:10.1007/s40265-021-01575-1. PMID 34357499.